📊 MGX Key Takeaways
Is Metagenomi Therapeutics, Inc. (MGX) a Good Investment?
Metagenomi is a pre-commercialization biotech company with minimal revenue ($1.2M, down 51.8% YoY) but unsustainable cash burn ($21.2M operating outflow annually). Despite a strong balance sheet ($137.8M equity, $25.3M cash, zero debt), the current burn rate provides only ~1.2 years of runway, and the company shows no clear path to profitability from available financial metrics.
Metagenomi Therapeutics shows very weak fundamentals, with revenue down sharply year over year and losses that are several times larger than revenue. While the balance sheet is currently debt-free and liquid, cash burn is extremely high relative to its cash balance, which raises material funding and dilution risk unless operating performance improves meaningfully.
Why Buy Metagenomi Therapeutics, Inc. Stock? MGX Key Strengths
- Strong balance sheet with $137.8M stockholders equity and zero debt
- Adequate near-term cash position of $25.3M with excellent liquidity ratios (6.43x current/quick)
- Minimal capital expenditure ($25K) suggests focused R&D allocation rather than infrastructure spending
- Strong near-term liquidity with current and quick ratios of 7.22x
- No meaningful long-term debt, limiting financial leverage risk
- Positive equity base of $158.60M provides some balance-sheet cushion
MGX Stock Risks: Metagenomi Therapeutics, Inc. Investment Risks
- Severe cash burn of $21.2M annually with negative operating cash flow, resulting in ~1.2 year runway at current burn rate
- Revenue collapsing (-51.8% YoY) from already minimal $1.2M base indicates commercialization challenges
- Massive operating losses (-$24.6M) and negative net margin (-1847.7%) with no visible path to profitability
- Early-stage biotech model dependent on pipeline success, regulatory approvals, and capital raise requirements
- Revenue declined 51.8% YoY, indicating weak and potentially volatile growth quality
- Operating and net margins are deeply negative, showing an unsustainable cost structure
- Operating cash outflow of $88.89M versus $41.72M cash suggests limited runway without additional capital
Key Metrics to Watch
- Monthly cash burn rate and remaining runway (critical for survival assessment)
- Revenue growth trajectory and any new product commercialization milestones
- Clinical pipeline progress and regulatory filing status for core candidates
- Capital raise activity and dilution impact on equity holders
- Quarterly cash burn versus cash and equivalents
- Revenue durability and collaboration-driven topline growth
Metagenomi Therapeutics, Inc. (MGX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.43x current ratio provides a solid financial cushion.
MGX Profit Margin, ROE & Profitability Analysis
MGX vs Healthcare Sector: How Metagenomi Therapeutics, Inc. Compares
How Metagenomi Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Metagenomi Therapeutics, Inc. Stock Overvalued? MGX Valuation Analysis 2026
Based on fundamental analysis, Metagenomi Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Metagenomi Therapeutics, Inc. Balance Sheet: MGX Debt, Cash & Liquidity
MGX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Metagenomi Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.36 indicates the company is currently unprofitable.
MGX Revenue Growth, EPS Growth & YoY Performance
MGX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.2M | -$23.1M | $-0.61 |
| Q3 2025 | $8.7M | -$10.7M | $-0.51 |
| Q2 2025 | $8.5M | -$10.7M | $-0.29 |
| Q1 2025 | $4.1M | -$25.0M | $-0.68 |
| Q3 2024 | $11.5M | -$10.7M | $-0.51 |
| Q2 2024 | $11.3M | -$10.7M | $-0.29 |
| Q1 2024 | $8.7M | -$16.1M | $-1.19 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Metagenomi Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
MGX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Metagenomi Therapeutics, Inc. (CIK: 0001785279)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MGX
What is the AI rating for MGX?
Metagenomi Therapeutics, Inc. (MGX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MGX's key strengths?
Claude: Strong balance sheet with $137.8M stockholders equity and zero debt. Adequate near-term cash position of $25.3M with excellent liquidity ratios (6.43x current/quick). ChatGPT: Strong near-term liquidity with current and quick ratios of 7.22x. No meaningful long-term debt, limiting financial leverage risk.
What are the risks of investing in MGX?
Claude: Severe cash burn of $21.2M annually with negative operating cash flow, resulting in ~1.2 year runway at current burn rate. Revenue collapsing (-51.8% YoY) from already minimal $1.2M base indicates commercialization challenges. ChatGPT: Revenue declined 51.8% YoY, indicating weak and potentially volatile growth quality. Operating and net margins are deeply negative, showing an unsustainable cost structure.
What is MGX's revenue and growth?
Metagenomi Therapeutics, Inc. reported revenue of $1.2M.
Does MGX pay dividends?
Metagenomi Therapeutics, Inc. does not currently pay dividends.
Where can I find MGX SEC filings?
Official SEC filings for Metagenomi Therapeutics, Inc. (CIK: 0001785279) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MGX's EPS?
Metagenomi Therapeutics, Inc. has a diluted EPS of $-0.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MGX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Metagenomi Therapeutics, Inc. has a SELL rating with 83% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MGX stock overvalued or undervalued?
Valuation metrics for MGX: ROE of -16.7% (sector avg: 15%), net margin of -1,847.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MGX stock in 2026?
Our dual AI analysis gives Metagenomi Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MGX's free cash flow?
Metagenomi Therapeutics, Inc.'s operating cash flow is $-21.2M, with capital expenditures of $25.0K. FCF margin is -1,698.7%.
How does MGX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,847.7% (avg: 12%), ROE -16.7% (avg: 15%), current ratio 6.43 (avg: 2).